MODD News & Events

Modular Medical announced submission to the U.S. Food & Drug Administration of a series of software enhancements to its Pivot insulin delivery system, providing users with more customization options and user-interface improvements, as well as other software upgrades.

Modular Medical announced that the first patients have completed onboarding and training and are now actively using the Pivot tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

Modular Medical announced that the Pivot tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across select metropolitan markets by late 2026.

Modular Medical announced that the Pivot, tubeless insulin patch pump, is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company. "Reaching commercial availability is a transformational milestone that marks Modular Medical's transition from a development-stage company to a revenue-generating commercial business," said Jeb Besser, Chief Executive Officer of Modular Medical. "As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved 'almost-pumper' population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders."